11/5
05:28 pm
xene
Xenon to Report Q3 2024 Financial Results on November 12, 2024 [Canadian Business Journal (Canada)]
Neutral
Report
Xenon to Report Q3 2024 Financial Results on November 12, 2024 [Canadian Business Journal (Canada)]
11/5
04:01 pm
xene
Xenon to Report Q3 2024 Financial Results on November 12, 2024
Neutral
Report
Xenon to Report Q3 2024 Financial Results on November 12, 2024
10/10
09:36 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $50.00 price target on the stock.
Low
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $50.00 price target on the stock.
10/2
04:28 pm
xene
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
Low
Report
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
10/1
07:57 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $53.00 price target on the stock.
Low
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $53.00 price target on the stock.
9/19
04:22 pm
xene
Life Sciences BC Announces Board Updates [Yahoo! Finance]
Low
Report
Life Sciences BC Announces Board Updates [Yahoo! Finance]
9/9
08:34 am
xene
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress [Financial Post (Toronto, Ontario, Canada)]
9/9
08:30 am
xene
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
Low
Report
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
9/6
07:02 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) was upgraded by analysts at William Blair to a "strong-buy" rating.
Medium
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) was upgraded by analysts at William Blair to a "strong-buy" rating.
9/5
01:24 am
xene
Xenon Pharmaceuticals Inc. (XENE): Among the Best Mid-Cap Healthcare Stocks To Buy Now [Yahoo! Finance]
Low
Report
Xenon Pharmaceuticals Inc. (XENE): Among the Best Mid-Cap Healthcare Stocks To Buy Now [Yahoo! Finance]
9/3
10:12 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
Low
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
8/26
08:06 am
xene
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely [Yahoo! Finance]
Low
Report
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely [Yahoo! Finance]
8/21
12:24 pm
xene
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe [Yahoo! Finance]
Low
Report
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe [Yahoo! Finance]
8/12
08:36 am
xene
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer [Financial Post (Toronto, Ontario, Canada)]
8/12
08:30 am
xene
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
Low
Report
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
8/12
08:04 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its price target lowered by analysts at Needham & Company LLC from $62.00 to $60.00. They now have a "buy" rating on the stock.
Low
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its price target lowered by analysts at Needham & Company LLC from $62.00 to $60.00. They now have a "buy" rating on the stock.
8/9
06:03 pm
xene
Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain [Seeking Alpha]
Low
Report
Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain [Seeking Alpha]
8/9
12:52 pm
xene
Xenon Pharmaceuticals, Inc. (XENE) Q2 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
Xenon Pharmaceuticals, Inc. (XENE) Q2 2024 Earnings Call Transcript [Seeking Alpha]
8/9
11:17 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Medium
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
8/9
10:20 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its price target lowered by analysts at Wedbush from $50.00 to $49.00. They now have an "outperform" rating on the stock.
Medium
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its price target lowered by analysts at Wedbush from $50.00 to $49.00. They now have an "outperform" rating on the stock.
8/8
04:09 pm
xene
Xenon Reports Q2 2024 Financial Results and Business Update [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Xenon Reports Q2 2024 Financial Results and Business Update [Financial Post (Toronto, Ontario, Canada)]
8/8
04:01 pm
xene
Xenon Reports Q2 2024 Financial Results and Business Update
Medium
Report
Xenon Reports Q2 2024 Financial Results and Business Update